TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC
Status:
Not yet recruiting
Trial end date:
2022-10-20
Target enrollment:
Participant gender:
Summary
Purpose：explore the effectiveness and safety of transarterial chemoembolization (TACE) plus
Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona
stage C hepatocellular carcinoma (HCC)